pd 153035 has been researched along with staurosporine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chandraratna, RA; Nagpal, S; Thacher, SM; Tsang, KY; Vasudevan, J | 1 |
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Axe, FU; Bembenek, SD; Butler, CR; Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Karlsson, L; Lundeen, K; Riley, JP; Savall, BM; Tays, KL; Wei, J; Williams, KN; Xue, X | 1 |
| Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA | 1 |
| Amendola, G; Barresi, E; Cosconati, S; Da Settimo, F; García-Argáez, AN; La Motta, C; Marini, AM; Novellino, E; Salerno, S; Simorini, F; Taliani, S; Tomassi, S; Via, LD | 1 |
| Antonelli, A; Botta, L; Coviello, V; Da Settimo, F; Fallahi, P; Ferrari, SM; Hsing-Pang, H; Ke, YY; La Motta, C; La Pietra, V; Marinelli, L; Moriconi, A; Novellino, E; Quattrini, L; Sartini, S | 1 |
1 review(s) available for pd 153035 and staurosporine
| Article | Year |
|---|---|
New dermatological agents for the treatment of psoriasis.
Topics: Administration, Topical; Anti-Inflammatory Agents; Cholecalciferol; Clinical Trials as Topic; Glucocorticoids; Humans; Immunosuppressive Agents; Ligands; Methotrexate; Psoriasis; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Vitamin A | 2001 |
5 other study(ies) available for pd 153035 and staurosporine
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Catalysis; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship | 2008 |
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2015 |
New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrans; Pyrimidines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Structure-Activity Relationship; Thyroid Gland; Thyroid Neoplasms | 2018 |